Gram-negative bacilli infections have become an increasingly serious problem among hospitalized patients. Many of these organisms are resistant to kanamycin sulfate. Recently, infections caused by gram-negative bacilli which are resistant to gentamicin sulfate have been reported (7) . Consequently, the search for new antibiotics continues to be of considerable importance.
Amikacin (BB-K8) is a new aminoglycoside antibiotic which is a chemical derivative of kanamycin (4) . The drug is of interest because it has broad-spectrum activity against gram-negative bacilli, including Pseudomonas aeruginosa (1, 6) . Amikacin is also active in vitro against many isolates of gram-negative bacilli which are resistant to other aminoglycoside antibiotics. Because of its potential value for the therapy of infections caused by gram-negative bacilli, pharmacological studies of amikacin were initiated.
MATERIALS AND METHODS
All patients included in this study had metastatic cancer or leukemia but were not debilitated. All had normal renal function as evidenced by a serum creatinine of 1.5 mg/100 ml or less and a blood urea nitrogen of 22 mg/100 ml or less. Creatinine clearances were obtained from most patients and were greater than 90 ml/min (corrected to a body surface area of 1.73 m2). All but two of the patients had normal liver function as evidenced by a normal bilirubin and serum glutamic oxalacetic transaminase (SGOT). The two exceptions were patients who received the drug as therapy for infections. The patients ranged in age from 14 to 62 years old (median 43 years old). Their body surface area varied from 1.4 m2 to 2.5 m2 (median 1.8 m2). Informed consent was obtained according to institutional policy.
Nine patients participated in single-dose studies of amikacin administered intramuscularly (i.m.) and intravenously (i.v.) at a dose of 300 mg/M2 of body surface area. The i.v. dose was given in 50 ml of 5% dextrose solution over 15 min. The same nine patients also received kanamycin sulfate (300 mg/M2) i.v. as above. The interval between each of the three studies was at least 2 days. Each of the three studies was conducted initially with one-third of the patients who were assigned on a random basis. Serum specimens were obtained before drug administration, and at 0.25, 0.5, 1, 2, 4, 6, and 8 h after drug administration. Urine specimens were collected before drug administration and during the first 6 h of the study.
Sixteen patients were studied while receiving amikacin as therapy for infections. Six patients received a dose of 150 mg/M2 every 6 The concentrations of amikacin and kanamycin sulfate in blood and urine specimens were determined by an agar well method with Bacillus subtilis ATCC 6633 as the test organism (3). The organism was incubated in brain heart infusion agar (BBL) for 1 week at 37 C, harvested, washed with normal saline, and heat-shocked at 65 C for 30 min to release the spores. The spores were washed and suspended in normal saline so that there were approximately 5 x 107 viable spores per ml. A 1.5-ml portion of this suspension was added to 1 liter of antibiotic medium no. 2, the pH was adjusted to 7.8 with phosphate buffer, and petri dishes were filled with 14-ml portions. Wells (0.75 mm in diameter and 0.4 mm in depth) were cut into the agar and filled with 0.05 ml of each specimen. The plates were incubated at 37 C for 18 h. Zones of inhibitioh were measured and compared to a standard curve. Assays were performed in triplicate.
The standard error of the mean was calculated by the method of Mantel (5) . The 95% confidence limits were calculated as twice the standard error of the mean. Statistical analyses of the differences in serum concentrations were performed with the Student's t test. The amikacin used in these studies was supplied by Bristol Laboratories, Syracuse, N.Y.
RESULTS
The mean serum concentrations obtained after the i.m. and i.v. administration of single doses of 300 mg of amikacin per M2 to the same nine patients are shown in Fig. 1 . The highest mean serum concentration after i.m. administration was 25.4 ,Ag/ml and was obtained at 30 min. The mean serum concentrations at 6 and 8 h were 7.0 Ag/.ml and 3.1 sg/ml, respectively.
The serum half-life was 2.8 h. The highest mean serum concentration after the 15-min i.v. infusion was obtained at the end of the infusion and was 52.4 gg/ml. The mean serum concentrations at 6 and 8 h were 4.0 ug/ml and 2.1 gg/ ml, respectively. The serum half-life was 2 h. The same nine patients also received 300 mg of kanamycin sulfate per mi2, administered i.v. over a 15-min period (Fig. 2) . The highest mean serum concentration was 45.0 ,ug/ml, and the mean serum concentrations at 6 and 8 h were 2.8 ,ug/ml and 1.6 ,ug/ml, respectively. The serum half-life was 1.9 h.
Five patients received a dose of 150 mg of amikacin per m2, administered i.v. over 30 min every 6 h as therapy for infections (Fig. 3) . Pharmacological studies were conducted on days 3 and 7 of therapy. On day 3, the initial mean serum concentration was 2.5 Ag/ml. The highest mean serum concentration was obtained at the end of the infusion and was 18.3 gg/ml. The mean serum concentration at 6 h (before initiation of the next infusion) was 2.4 ,ug/ml. On day 7, the initial mean serum concentration was 4 serum concentration was 20.6 Ag/ml and the mean serum concentration at 6 h was 3.9 ,g/ml.
The serum half-life on day 3 was 1.7 h and on day 7 was 1.9 h. The differences between the serum concentrations on day 3 and day 7 were statistically significant for every sampling period except the 15-min samples (P = <0.02 to 0.05).
Ten patients received a loading dose of amikacin followed by a continuous i.v. infusion as therapy for infections (Fig. 4) No toxicity was observed after the single-dose studies of amikacin. None of the patients receiving multiple-dosage regimens developed nephrotoxicity or ototoxicity. However, elevations in SGOT were observed in 8 of these 15 patients during therapy with amikacin. Six of the patients received the drug as a continuous i.v. infusion. In most of the patients other factors such as antitumor agents were a more likely explanation for these abnormalities.
Serum specimens obtained from the patients receiving 150 mg of amikacin per m2 every 6 h were tested in vitro against isolates of gram-negative bacilli (Fig. 5 ). The specimens tested had been collected on day 3 of therapy, just before an infusion and at the end of the 30-min infusion. Six isolates each of P. aeruginosa, Klebsiella spp., and Escherichia coli were used. Three isolates each had a minimal inhibitory concentration (MIC) of 0.78 yg/ml, and the remaining had an MIC of 3.12 ,g/ml. Twofold serial dilutions of each specimen were made, and the greatest dilution which inhibited the growth of each organism was determined. There was good correlation between the serum inhibitory activity and the actual serum concentration. For example, a serum concentration of 6.3 ,ug/ml would be expected to inhibit an organism with an MIC of 0.78 ,g/ml at a 1 :'8 dilution. The majority of isolates of P. aeruginosa were not inhibited by the expected serum dilution, whereas a majority of the isolates of Klebsiella spp. were more sensitive than expected.
DISCUSSION
Amikacin is a new aminoglycoside antibiotic of potential importance because of its broadspectrum activity against gram-negative bacilli, regimen, it may be possible to administer even higher doses safely.
Aminoglycoside antibiotics are excreted mainly by glomerular filtration and are not metabolized in the body. Over 70% of amikacin was excreted in the urine during the first 6 h after an i.m. dose and 66% was excreted after an i.v. dose. Urinary excretion of kanamycin sulfate was similar to amikacin.
The activity of amikacin in the patient serum correlated with the serum concentration and the in vitro sensitivity of the organisms tested. Hence, serum factors do not significantly interfere with the activity of this antibiotic against some gram-negative bacilli. However, its activity against P. aeruginosa was suboptimal, suggesting that serum factors may interfere with the activity of amikacin against this organism. The activity of some aminoglycoside antibiotics against P. aeruginosa is reduced in the presence of magnesium and calcium (2) .
A dose of 300 mg/m2 (7.5 mg/kg) every 12 h or 200 mg/m2 every 8 h i.m. of amikacin probably will be adequate for the treatment of many infections, especially urinary tract infections. However, patients with serious infections may benefit from more frequent dosage (150 mg/m2 every 6 h). For patients with impaired host defense mechanisms it may be more important to maintain adequate serum concentrations. A regimen of 150 mg/m2 as a loading dose followed by 200 mg/m2 every 6 h maintains serum concentrations of at least 8 jg/ml, which should be adequate against most organisms.
